Adverse effect · Eloralintide

How common is nausea and fatigue with Eloralintide?

C
Grade C — weak human evidenceSame RCT · effect size: moderate · adverse
Short answerWeak human evidence. Same RCT: enough to be interesting, not enough to count on. Where an effect is seen it is a moderate effect. Nausea reached 64% at the 6 mg fixed dose and was lower with escalation. Fatigue in up to 46% — a side effect the GLP-1 drugs do not produce at that rate, and one to watch in phase 3.

What the studies show

Nausea reached 64% at the 6 mg fixed dose and was lower with escalation. Fatigue in up to 46% — a side effect the GLP-1 drugs do not produce at that rate, and one to watch in phase 3.

“The most common adverse events with eloralintide were nausea (1 mg 11%, 3 mg 13%, 6 mg 64%, 9 mg 33%, 6-9 mg 54%, 3-9 mg 25%, and placebo 14%) and fatigue (1 mg 0%, 3 mg 13%, 6 mg 29%, 9 mg 43%, 6-9 mg 46%, 3-9 mg 21%, and placebo 12%).”

Verbatim, from the abstractBillings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, 2025

A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.

  1. 1

In context

Eloralintide is a once-weekly amylin receptor agonist from Eli Lilly, tested on its own and, more recently, paired with tirzepatide. In a 263-person phase 2 trial published in The Lancet in 2025, the top doses produced about 20% weight loss at 48 weeks against 0.4% on placebo. Nausea was dose-dependent and fatigue was unusually common. Added to tirzepatide in a phase 2b trial reported by press release in September 2026, it took weight loss in people with type 2 diabetes from 14.8% to 23.3% at 48 weeks. Phase 3 trials are running; it is not approved anywhere.

Eloralintide is investigational (phase 3). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Eloralintide proven to cause nausea and fatigue?
No. The human evidence is weak (Same RCT); LYO grades it C.
What studies are behind the grade?
Nausea reached 64% at the 6 mg fixed dose and was lower with escalation. Fatigue in up to 46% — a side effect the GLP-1 drugs do not produce at that rate, and one to watch in phase 3.
Is Eloralintide approved for this?
No. Eloralintide is investigational (phase 3); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Eloralintide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →